12/31/2015
`
`New Copaxone Formulation Could Help Teva Retain Market Share | AIS Health
`
`Home About AIS Contact AIS Customer Service Advertising & Sponsorships
`
`My Account
`
` My Cart
`
` Log In
`
`Search AISHealth.com
`
`Upcoming Webinar Jan 20, 2016
`Oral Oncology Drugs: Health Plan
`Strategies for a Dynamic Market
`
`MarketPlace AIS Blogs ENewsletters
`
`Search
`
`Renewal Center Advertising & Sponsorships
`
`Already a member? Log in
`
`AIS Blogs › Pharmacy Benefit Management › New Copaxone Formulation Could Help Teva Retain Market Share
`
`New Copaxone Formulation Could Help Teva Retain
`Market Share
`
`By Angela Maas February 19, 2014
`
`Like
`
`0
`
` Print
`
`With market share eroding for Teva’s multiple sclerosis therapy Copaxone (glatiramer acetate),
`the manufacturer recently launched a new formulation of the drug that could help it retain its
`footing. And a somewhat different approach in pricing for the new version could seal the deal.
`
`Copaxone was approved in 1996 with daily 20 mg/mL dosing. But the new 40 mg/mL version is
`administered three times a week and offers “essentially equivalent efficacy as the 20 mg dosing level,”
`Stephen Cichy, founder and managing director at Monarch Specialty Group, LLC, tells Specialty Pharmacy
`News. However, it also provides “a simpler dosing regimen. Injections three times per week versus daily”
`means “the sole focus of the new formulation is on injection fatigue.”
`
`While the original formulation will remain available, Teva has said it hopes to convert people on that drug to
`the newer formulation. With Copaxone’s patent due to expire in May, the sooner that could happen, the better.
`
`It's quick and easy to sign up for FREE
`access to AISHealth.com!
`
`According to Boris Gorsh, a manager of syndicated research at Zitter Health Insights, the Wholesale
`Acquisition Cost (WAC) for the new Copaxone formulation is $4,641.24 per month — a decrease from the
`$5,060.33 per month Copaxone daily. Pricing the new formulation a little less than the 20 mg version “is an
`interesting strategy as it is cheaper than daily Copaxone, which can be related to the requirement of less
`syringes, but also to encourage payers to allow patients to make the switch prior to a generic version,” he
`says.
`
`Why do I need to register?
`
`About the AIS Bloggers
`Jill Brown
`Executive Editor
`View Jill's Profile
`
`While Teva makes the 20 mg formulation available for a $35 copay, the company is waiving copays
`indefinitely for the 40 mg, which is an additional incentive for people to switch, points out David Lassen, chief
`clinical officer at Prime Therapeutics LLC. For payers, “Since this is a new formulation of an existing drug with
`similar safety and efficacy profiles, pricing will be a determining factor. The dosing advantage will also come
`into consideration.”
`
`What do you think of this Teva strategy? Can you see other drugmakers adopting it?
`
`To request a free sample copy of Angela’s newsletter, Specialty Pharmacy News, send an email to
`goliver@aishealth.com.
`
`Patrick Connole
`Managing Editor, Health
`Plan Week
`View Patrick's Profile
`
`Steve Davis
`Managing Editor, Inside
`Health Insurance
`Exchanges and The AIS
`Report on Blue Cross and
`Blue Shield Plans*
`View Steve's Profile
`
`Francie Fernald
`Managing Editor
`View Francie's Profile
`
`James Gutman
`Managing Editor, Medicare
`Advantage News
`View James's Profile
`
`Angela Maas
`Managing Editor, Specialty
`Pharmacy News, Drug
`Benefit News and AIS E
`Media
`View Angela's Profile
`
`Nina Youngstrom
`
`http://aishealth.com/blog/pharmacy-benefit-management/new-copaxone-formulation-could-help-teva-retain-market-share
`
`1/2
`
`MYLAN PHARMS. INC. EXHIBIT 1122 PAGE 1
`
`
`
`New Copaxone Formulation Could Help Teva Retain Market Share | AIS Health
`
`Home About AIS Contact AIS Customer Service Advertising & Sponsorships
`
`My Account
`
` My Cart
`
` Log In
`
`Search AISHealth.com
`
`Upcoming Webinar Jan 20, 2016
`Oral Oncology Drugs: Health Plan
`Strategies for a Dynamic Market
`
`MarketPlace AIS Blogs ENewsletters
`
`Search
`
`Renewal Center Advertising & Sponsorships
`
`Already a member? Log in
`
`AIS Blogs › Pharmacy Benefit Management › New Copaxone Formulation Could Help Teva Retain Market Share
`
`New Copaxone Formulation Could Help Teva Retain
`Market Share
`
`By Angela Maas February 19, 2014
`
`Like
`
`0
`
`
`With market share eroding for Teva’s multiple sclerosis therapy Copaxone (glatiramer acetate),
`the manufacturer recently launched a new formulation of the drug that could help it retain its
`footing. And a somewhat different approach in pricing for the new version could seal the deal.
`
`Copaxone was approved in 1996 with daily 20 mg/mL dosing. But the new 40 mg/mL version is
`administered three times a week and offers “essentially equivalent efficacy as the 20 mg dosing level,”
`Stephen Cichy, founder and managing director at Monarch Specialty Group, LLC, tells Specialty Pharmacy
`News. However, it also provides “a simpler dosing regimen. Injections three times per week versus daily”
`means “the sole focus of the new formulation is on injection fatigue.”
`
`While the original formulation will remain available, Teva has said it hopes to convert people on that drug to
`the newer formulation. With Copaxone’s patent due to expire in May, the sooner that could happen, the better.
`
`It's quick and easy to sign up for FREE
`access to AISHealth.com!
`
`According to Boris Gorsh, a manager of syndicated research at Zitter Health Insights, the Wholesale
`Acquisition Cost (WAC) for the new Copaxone formulation is $4,641.24 per month — a decrease from the
`$5,060.33 per month Copaxone daily. Pricing the new formulation a little less than the 20 mg version “is an
`interesting strategy as it is cheaper than daily Copaxone, which can be related to the requirement of less
`syringes, but also to encourage payers to allow patients to make the switch prior to a generic version,” he
`says.
`
`Why do I need to register?
`
`About the AIS Bloggers
`Jill Brown
`Executive Editor
`View Jill's Profile
`
`While Teva makes the 20 mg formulation available for a $35 copay, the company is waiving copays
`indefinitely for the 40 mg, which is an additional incentive for people to switch, points out David Lassen, chief
`clinical officer at Prime Therapeutics LLC. For payers, “Since this is a new formulation of an existing drug with
`similar safety and efficacy profiles, pricing will be a determining factor. The dosing advantage will also come
`into consideration.”
`
`What do you think of this Teva strategy? Can you see other drugmakers adopting it?
`
`To request a free sample copy of Angela’s newsletter, Specialty Pharmacy News, send an email to
`goliver@aishealth.com.
`
`Patrick Connole
`Managing Editor, Health
`Plan Week
`View Patrick's Profile
`
`Steve Davis
`Managing Editor, Inside
`Health Insurance
`Exchanges and The AIS
`Report on Blue Cross and
`Blue Shield Plans*
`View Steve's Profile
`
`Francie Fernald
`Managing Editor
`View Francie's Profile
`
`James Gutman
`Managing Editor, Medicare
`Advantage News
`View James's Profile
`
`Angela Maas
`Managing Editor, Specialty
`Pharmacy News, Drug
`Benefit News and AIS E
`Media
`View Angela's Profile
`
`Nina Youngstrom
`
`http://aishealth.com/blog/pharmacy-benefit-management/new-copaxone-formulation-could-help-teva-retain-market-share
`
`1/2
`
`MYLAN PHARMS. INC. EXHIBIT 1122 PAGE 1
`
`
`
`12/31/2015
`0 Comments
`
`AISHealth
`
` Recommend
`
`
`
` Share⤤
`
`Start the discussion…
`
`New Copaxone Formulation Could Help Teva Retain Market Share | AIS Health
`Managing Editor, Report on
` Login
`Medicare Compliance
`View Nina's Profile
`
`1
`Sort by Best
`
`Theresa
`Defino
`Editor,
`Report on
`Patient
`Privacy and Report on Research
`Compliance
`View Theresa's Profile
`
`Lauren Flynn Kelly
`Editor, Drug Benefit News
`View Lauren's Profile
`
`Lauren Clason
`Associate Editor, Report on
`Patient Privacy
`View Lauren's Profile
`
`Rick Biehl
`President & Publisher
`View Rick's Profile
`
`AIS Staff
`View AIS's Profile
`
`Featured Pharmacy Benefit
`Management Products
`Quality Programs in Cancer Care: A
`Case Study of the Aetna Model
`Specialty Pharmacy News
`Drug Benefit News
`Oral Oncology Drugs: Health Plan
`Strategies for a Dynamic Market
`Specialty Pharmacy Trends and
`Strategies: 2015
`Strategies for Making ValueBased
`Rx Deals in a VolumeBased World
`
`Visit the MarketPlace
`
`ALSO ON AISHEALTH
`How Can We Bring Down the High Prices
`of Drugs?
`1 comment • 2 years ago
`Roger — Alternative and herbal
`complimentary medicine including
`acupuncture to reduce the dosage and …
`Iowa CO-OP Is in ‘Hazardous Financial
`Condition’…Are More at Risk?
`2 comments • a year ago
`AvatarShoreman2 — My father had a saying for
`government plans like this, he called them
`Vast new programs built on half vast ideas. …
`
`WHAT'S THIS?
`How Many CO-OPs Will Be Left in 2016?
`1 comment • 4 months ago
`Marlin McKelvy — Of course, this will be
`another largely failed experiment foisted upon
`the American public as we have seen with …
`
`WellCare: Is This the End of the Beginning
`or the Beginning of the End?
`1 comment • 2 years ago
`AvatarBart Smith — And now a few months later,
`look at WellCare's earnings and stock price.
`The "interim" CEO has no health care …
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site Add Disqus Add
`
`Privacy
`
`
`
`Marketplace
`
` About AIS
`
` Contact AIS
`
` Press Releases
`
` Customer Service
`
` Renew Subscription
`
` Advertising & Sponsorships
`
` FAQs
`
` My Cart
`
`Atlantic Information Services, Inc. 1100 17th Street NW, Suite 300, Washington, DC 20036 8005214323
`Copyright © 2015 Atlantic Information Services, Inc. All Rights Reserved.
`
`Sitemap Privacy Policy Back to Top
`
`Follow @AISHealth
`
`http://aishealth.com/blog/pharmacy-benefit-management/new-copaxone-formulation-could-help-teva-retain-market-share
`
`2/2
`
`Be the first to comment.
`
`MYLAN PHARMS. INC. EXHIBIT 1122 PAGE 2
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
